Foundayo vs. the Wegovy pill: evidence, cost and who qualifies
Foundayo and the Wegovy pill are daily GLP-1 weight-loss pills. No head-to-head trial exists. Here is what the data shows, plus cost and eligibility.
GoGLP1 earns a commission from qualifying provider enrollments via links on this page. This never affects our editorial rankings or reviews. Full disclosure.
Two daily GLP-1 pills are now available for weight loss: Lilly’s Foundayo (orforglipron) and the Wegovy pill (oral semaglutide 25 mg). Each drug has one pivotal trial behind it. No trial has compared them directly.
That gap matters. The headline numbers invite a ranking the data can’t support. Here’s what each trial found, what the one indirect comparison suggests, what Foundayo costs, and who can take it.
What Foundayo is
Foundayo is a once-daily oral GLP-1 receptor agonist. It’s a non-peptide, small-molecule drug, according to Lilly’s announcement. Lilly says you can take it any time of day, with no food or water restrictions. That’s press-release language, so check the dosing section of the prescribing information for the exact instructions.
The Wegovy pill is oral semaglutide, a peptide drug with its own administration requirements. We haven’t verified those, so read the Wegovy label before assuming the two pills are taken the same way. For how the pill differs from the injection, see our guide to the Wegovy pill versus the injection.
Who it is approved for
The FDA label for Foundayo covers use alongside a reduced-calorie diet and more physical activity, with the goals of reducing excess body weight and keeping it off long term. It is for:
- Adults with obesity.
- Adults with overweight who have at least one weight-related condition.
Press coverage and Lilly’s announcement put the approval at April 1, 2026. We confirmed that date only in search summaries, not on the FDA page.
Who should not take it
Per the Lilly prescribing information, Foundayo is contraindicated in people with:
- A personal or family history of medullary thyroid carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- A known serious hypersensitivity to orforglipron or its excipients.
The label notes that orforglipron did not produce tumors in rodents. It also says the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors seen in rodents has not been determined. We could read that wording only in search-result text, not in the full FDA PDF.
What the Foundayo trial showed
The pivotal trial is ATTAIN-1, published in the New England Journal of Medicine in September 2025. It randomized 3,127 adults with obesity and without diabetes to orforglipron 6, 12 or 36 mg once daily, or placebo, for 72 weeks. Eli Lilly funded the work.
Mean body-weight change:
| Group | Weight change at 72 weeks |
|---|---|
| Orforglipron 6 mg | -7.5% |
| Orforglipron 12 mg | -8.4% |
| Orforglipron 36 mg | -11.2% |
| Placebo | -2.1% |
Every dose beat placebo by a significant margin (95% CI for placebo -2.8 to -1.4; P<0.001). At 36 mg, 54.6% of participants lost 10% or more of their body weight, versus 12.9% on placebo.
Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol also improved versus placebo.
Safety in ATTAIN-1
Adverse events led to stopping treatment in 5.3% to 10.3% of patients across the orforglipron groups, versus 2.7% on placebo. The most common events were gastrointestinal and mostly mild to moderate.
Long-term safety, cardiovascular outcomes and weight regain after stopping sit outside this article. They matter for a drug meant to be taken for years. For what happens when people stop other GLP-1s, see our summary of studies on stopping Ozempic and Wegovy.
What the Wegovy pill trial showed
The Wegovy pill rests on OASIS 4, published in NEJM in September 2025. It tested oral semaglutide 25 mg once daily. The trial randomized 307 adults with overweight or obesity and no diabetes: 205 to semaglutide, 102 to placebo. It ran 64 weeks.
Mean weight change came in at -13.6% with semaglutide and -2.2% with placebo, a difference of -11.4 percentage points (95% CI -13.9 to -9.0; P<0.001).
On side effects, gastrointestinal events were more common with oral semaglutide than placebo: 74.0% versus 42.2%. The PubMed abstract we read didn’t state a discontinuation rate for adverse events, so we can’t compare that figure with ATTAIN-1.
Why the numbers are not a ranking
Put the two results side by side and semaglutide looks ahead: roughly 14% against roughly 11% weight loss. Don’t read that as a verdict. The trials differ in several ways:
- Length. ATTAIN-1 ran 72 weeks. OASIS 4 ran 64.
- Size. ATTAIN-1 enrolled 3,127 people. OASIS 4 enrolled 307.
- Titration. The dose-escalation schedules were different.
- Population. The trials enrolled different groups of people.
- Sponsors. Both pivotal trials were sponsor-funded.
The placebo arms looked similar (-2.1% and -2.2%), which is mildly reassuring. It doesn’t erase the other differences. And the 11.2% figure is for the top 36 mg dose. Lower doses produced less weight loss in ATTAIN-1.
The one indirect comparison
We found no head-to-head trial of Foundayo versus the Wegovy pill. One group did run a population-adjusted indirect comparison of OASIS 4 (205 people on semaglutide) against ATTAIN-1 (730 people on orforglipron 36 mg).
It estimated greater weight loss with oral semaglutide:
- Treatment-regimen estimand: a difference of -3.2 percentage points (95% CI -5.9 to -0.4).
- Efficacy estimand: the gap narrowed to -3.0 points (95% CI -5.8 to -0.3).
- Responder rates: no significant differences in the proportions reaching 5%, 10%, 15% or 20% weight loss.
- Discontinuation: higher with orforglipron. The odds ratio was 4.1 for any adverse event (95% CI 1.3 to 13.0) and 13.9 for gastrointestinal events (95% CI 2.0 to 96.0).
Read those last numbers with care. A gastrointestinal confidence interval running from 2.0 to 96.0 tells you how imprecise the estimate is.
The authors themselves call indirect comparisons less reliable than head-to-head randomized trials. They flag differences in titration schedules, lifestyle interventions and populations: ATTAIN-1 was 29% Asian, while OASIS 4 was predominantly White.
The fair summary: a small edge for semaglutide on average weight loss is plausible, the confidence intervals are wide, and the method has real limits. A direct trial would settle it. Until then, neither pill can be called the winner.
What Foundayo costs
Prices change, and we couldn’t load Lilly’s pricing page directly. The figures below come from search-result text. Check them against the live page.
Self-pay. Lilly lists Foundayo through LillyDirect from $149 per month at the lowest dose:
- 2.5 mg: $149
- 5.5 mg: $199
- 9 mg: $299
The 2.5 mg and 5.5 mg prices are temporarily reduced through December 31, 2026. Higher doses cost more, and the Lilly page is the place to confirm current tiers. Our guide to GLP-1 costs without insurance covers other self-pay routes.
Commercial insurance. Per Lilly’s announcement, commercially insured people who have Foundayo coverage and qualify for the savings card may pay as little as $25 per month.
Medicare Part D. The same announcement says eligible Part D enrollees may be able to get Foundayo for $50 per month beginning July 1, 2026. Both offers depend on plan coverage and eligibility, and we didn’t verify the program terms. For related federal programs, see our explainer on the Medicare GLP-1 bridge program.
We didn’t research Wegovy pill pricing, so there’s no cost comparison here. Check novonordisk.com for that. Nothing here shows what any individual will pay.
Frequently Asked Questions
Who qualifies for Foundayo?
The label covers adults with obesity, or adults with overweight plus at least one weight-related condition, used alongside diet and activity changes. It requires a prescription. People with a personal or family history of medullary thyroid carcinoma or MEN 2, or a serious hypersensitivity to orforglipron, shouldn’t take it. We couldn’t verify BMI cut-offs from the label text we could read. A clinician decides.
Does Foundayo work as well as the Wegovy pill?
No head-to-head trial exists. The separate trials showed 11.2% weight loss (ATTAIN-1, 36 mg, 72 weeks) versus 13.6% (OASIS 4, 64 weeks), with placebo arms at 2.1% and 2.2%. The one indirect comparison favored semaglutide by about 3 percentage points, with wide confidence intervals and the caveats above. It doesn’t declare a winner, and neither do we.
How much does Foundayo cost?
Lilly lists self-pay from $149 per month at the lowest dose, with higher prices at higher doses. Some prices are temporarily reduced through December 31, 2026. Insured patients may pay as little as $25 per month with a savings card. Eligible Medicare Part D enrollees may pay $50 per month from July 1, 2026. Check LillyDirect and your plan. Our page on GLP-1 coupons and discounts lists other ways to lower the price.
What are the side effects?
In the trials, side effects were mostly gastrointestinal and mild to moderate. In ATTAIN-1, 5.3% to 10.3% of people on orforglipron stopped treatment due to adverse events, versus 2.7% on placebo. In OASIS 4, gastrointestinal events occurred in 74.0% on semaglutide versus 42.2% on placebo. We didn’t capture exact per-event percentages from the label.
Can people with type 2 diabetes use it for weight loss?
ATTAIN-2 studied adults with obesity or overweight and type 2 diabetes. We saw it only through secondary summaries. It showed less weight loss than ATTAIN-1, with a safety profile similar to other GLP-1 receptor agonists. We didn’t verify whether the weight-management label restricts use for people with diabetes. Ask your prescriber.
The bottom line
Foundayo has solid, large-trial evidence behind it: 11.2% average weight loss at the top dose over 72 weeks, against 2.1% on placebo. The Wegovy pill posted a higher figure in a much smaller, shorter trial. The indirect comparison hints at a modest semaglutide advantage but can’t confirm one.
For most people, the practical questions are coverage, price, tolerability and what a clinician recommends. Confirm prices on the live Lilly pages before you decide.
This article is for informational purposes only and is not medical advice. Talk to your healthcare provider before starting, stopping, or changing any medication.
Ready to start?
Our top-rated GLP-1 providers, reviewed and tested. We may earn a commission — see our editorial policy.
Affiliate disclosure: GoGLP1 earns a commission from qualifying enrollments. This never affects our rankings or reviews. Reviewed 2026.